Cargando…

Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City

BACKGROUND: Ovarian cancer is the most common fatal malignancy of the gynecology tract. The purpose of this study was to compare serum levels of tumor markers cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in both healthy groups and patients with ovarian cancer. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakrani, Mahnaz, Poor, Kahin Shahani, Mehrzad, Valiollah, Razmi, Nematallah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672644/
https://www.ncbi.nlm.nih.gov/pubmed/29142887
http://dx.doi.org/10.4103/2277-9175.216778
_version_ 1783276473449185280
author Bakrani, Mahnaz
Poor, Kahin Shahani
Mehrzad, Valiollah
Razmi, Nematallah
author_facet Bakrani, Mahnaz
Poor, Kahin Shahani
Mehrzad, Valiollah
Razmi, Nematallah
author_sort Bakrani, Mahnaz
collection PubMed
description BACKGROUND: Ovarian cancer is the most common fatal malignancy of the gynecology tract. The purpose of this study was to compare serum levels of tumor markers cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in both healthy groups and patients with ovarian cancer. MATERIALS AND METHODS: this case–control study was performed on Seyed Al-Shohada Hospital in Isfahan. Research on the treatment of 44 patients with ovarian cancer and 44 healthy controls was performed. CA125 and HE4 were measured in serum by sandwich ELISA method. RESULTS: Average CA125 in ovarian cancer patients (83.30 ± 43.99 μ/ml) was significantly higher than in healthy controls (12.39 ± 5.50 μ/ml) (P < 0.001). Average HE4 in ovarian cancer patients (295.41 ± 133.33 PM) was significantly higher than in healthy controls (114.64 ± 17.31 PM) (P < 0.001). CONCLUSIONS: HE4 test is complementary of CA125 test in women with epithelial ovarian cancer. It is also used to study the disease process.
format Online
Article
Text
id pubmed-5672644
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-56726442017-11-15 Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City Bakrani, Mahnaz Poor, Kahin Shahani Mehrzad, Valiollah Razmi, Nematallah Adv Biomed Res Original Article BACKGROUND: Ovarian cancer is the most common fatal malignancy of the gynecology tract. The purpose of this study was to compare serum levels of tumor markers cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in both healthy groups and patients with ovarian cancer. MATERIALS AND METHODS: this case–control study was performed on Seyed Al-Shohada Hospital in Isfahan. Research on the treatment of 44 patients with ovarian cancer and 44 healthy controls was performed. CA125 and HE4 were measured in serum by sandwich ELISA method. RESULTS: Average CA125 in ovarian cancer patients (83.30 ± 43.99 μ/ml) was significantly higher than in healthy controls (12.39 ± 5.50 μ/ml) (P < 0.001). Average HE4 in ovarian cancer patients (295.41 ± 133.33 PM) was significantly higher than in healthy controls (114.64 ± 17.31 PM) (P < 0.001). CONCLUSIONS: HE4 test is complementary of CA125 test in women with epithelial ovarian cancer. It is also used to study the disease process. Medknow Publications & Media Pvt Ltd 2017-10-16 /pmc/articles/PMC5672644/ /pubmed/29142887 http://dx.doi.org/10.4103/2277-9175.216778 Text en Copyright: © 2017 Advanced Biomedical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bakrani, Mahnaz
Poor, Kahin Shahani
Mehrzad, Valiollah
Razmi, Nematallah
Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title_full Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title_fullStr Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title_full_unstemmed Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title_short Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City
title_sort comparison of the serum level of cancer antigen 125 and human epididymis protein 4 in ovarian cancer patients and healthy groups in isfahan city
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672644/
https://www.ncbi.nlm.nih.gov/pubmed/29142887
http://dx.doi.org/10.4103/2277-9175.216778
work_keys_str_mv AT bakranimahnaz comparisonoftheserumlevelofcancerantigen125andhumanepididymisprotein4inovariancancerpatientsandhealthygroupsinisfahancity
AT poorkahinshahani comparisonoftheserumlevelofcancerantigen125andhumanepididymisprotein4inovariancancerpatientsandhealthygroupsinisfahancity
AT mehrzadvaliollah comparisonoftheserumlevelofcancerantigen125andhumanepididymisprotein4inovariancancerpatientsandhealthygroupsinisfahancity
AT razminematallah comparisonoftheserumlevelofcancerantigen125andhumanepididymisprotein4inovariancancerpatientsandhealthygroupsinisfahancity